-
Cardiovasc Diabetol: Effects of DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors on Cardiorenal Outcomes
Time of Update: 2022-05-12
DPP-4i: dipeptidyl peptidase-4 inhibitor; PL: placebo; GLP-1RA: glucagon-like peptide-1 receptor agonist; SGLT-2i: sodium-glucose co-transporter-2 inhibitorFigure 2 Forest plot of the meta-analysis network for cardiovascular death, total death, heart failure hospitalization, and renal outcomes .
-
Association of GLP-1 receptor agonist and DPP-4 inhibitor use with mortality in patients with type 2 diabetes and advanced chronic kidney disease
Time of Update: 2022-04-20
In conclusion, the results of this study show that GLP-1 receptor agonist treatment is associated with reduced all-cause mortality in patients with type 2 diabetes, advanced CKD and ESKD compared with DPP-4 inhibitors .
-
Cardiovasc Diabetol: GLP-1 receptor agonist VS basal insulin-for comparison of cardiovascular outcomes after conventional treatment of type 2 diabetes
Time of Update: 2021-12-02
Diabetes Metformin management consensus researchers want to verify, whether to start the GLP-1RA in routine clinical practice in T2D patients showed better heart vascular outcomes, and to this end a regional retrospective study .
-
Diabetes Treated with GLP-1 Receptor Agonists-A systematic review and meta-analysis of randomized trials
Time of Update: 2021-12-01
Two types of anti-glycemic drugs-GLP-1 receptor agonists and SGLT2 inhibitors can reduce the risk of high-risk patients with type 2 diabetesHeart vascular events . GLP-1 receptor agonists reduce gly
-
West China Hospital takes the lead to publish BMJ: SGLT-2 inhibitor/GLP-1 receptor agonist treatment of type 2 diabetes
Time of Update: 2021-06-11
▎The content team editor of WuXi AppTec recently, The BMJ published international clinical practice guidelines, recommending SGLT-2 inhibitors or GLP-1 receptor agonists for adult type 2 diabetes, focusing on different For patients with heart and kidney risk, the benefits and harms of these two types of drugs combined with routine diagnosis and treatment (life>The guidelines are jointly formulated by clinical and methodological experts from more than ten countries around the world.
-
BMJ: SGLT-2 inhibitor/GLP-1 receptor agonist treatment of type 2 diabetes
Time of Update: 2021-06-08
Recently, The British Medical Journal (The BMJ) published international clinical practice guidelines, recommending SGLT-2 inhibitors or GLP-1 receptor agonists for adult type 2 diabetes, focusing on patients with different heart and kidney risks, and evaluating The benefits and harms of these two types of drugs combined with conventional diagnosis and treatment (life>The guidelines are jointly formulated by clinical and methodological experts from more than ten countries around the world.
-
EU approves type 2 diabetes drug GLP-1 receptor agonist Rybelsus
Time of Update: 2020-06-25
Novo Nordisk today announced that the European Medicines Agency (EMA) has approved the sale of the company's oral GLP-1 receptor agonisant Rybelsus (semaglutide) to help control blood sugar in peopl
